Does MapLight Therapeutics, Inc. have the clinical design to compete in crowded neuropsychiatric markets?
MapLight Therapeutics nears key Phase 2 data in schizophrenia and autism. Discover how its trial design could shape CNS market competition.
Biohaven ends psychiatric push for BHV-7000 after Phase 2 trial in depression fails to show efficacy
Biohaven Ltd. has reported that BHV-7000, its experimental Kv7 ion channel modulator, failed to meet the primary endpoint in a Phase 2 proof-of-concept trial evaluating the drug in patients with major depressive disorder. The trial assessed changes in depressive symptoms using the Montgomery-Åsberg Depression Rating Scale over six weeks compared to placebo. Although some numerical […]